A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Clopidogrel; Prasugrel
- Indications Coronary artery disease; Embolism and thrombosis; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms OPTIMUS-3
- 31 Aug 2018 Biomarkers information updated
- 30 Aug 2010 Results have been presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology.
- 16 Nov 2009 Results presented at the 82nd Annual Scientific Sessions of the American Heart Association (AHA).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History